Circulating microRNA-155-3p levels predicts response to first line immunotherapy in patients with metastatic renal cell carcinoma
Abstract Predictive biomarkers of response to immune checkpoint-based therapies (ICI) remain a critically unmet need in the management of advanced renal cell carcinoma (RCC). The complex interplay of the tumour microenvironment (TME) and the circulating immune response has proven to be challenging t...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-04-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-024-59337-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850206103544004608 |
|---|---|
| author | Maryam Soleimani Marisa Thi Sajjad Janfaza Gizem Ozcan Sylwia Mazurek Guliz Ozgun Corinne Maurice-Dror Bernhard Eigl Kim Chi Christian Kollmannsberger Lucia Nappi |
| author_facet | Maryam Soleimani Marisa Thi Sajjad Janfaza Gizem Ozcan Sylwia Mazurek Guliz Ozgun Corinne Maurice-Dror Bernhard Eigl Kim Chi Christian Kollmannsberger Lucia Nappi |
| author_sort | Maryam Soleimani |
| collection | DOAJ |
| description | Abstract Predictive biomarkers of response to immune checkpoint-based therapies (ICI) remain a critically unmet need in the management of advanced renal cell carcinoma (RCC). The complex interplay of the tumour microenvironment (TME) and the circulating immune response has proven to be challenging to decipher. MicroRNAs have gained increasing attention for their role in post-transcriptional gene expression regulation, particularly because they can have immunomodulatory properties. We evaluated the presence of immune-specific extracellular vesicle (EV) microRNAs in the plasma of patients with metastatic RCC (mRCC) prior to initiation of ICI. We found significantly lower levels of microRNA155-3p (miR155) in responders to ICI, when compared to non-responders. This microRNA has unique immunomodulatory properties, thus providing potential biological rationale for our findings. Our results support further work in exploring microRNAs as potential biomarkers of response to immunotherapy. |
| format | Article |
| id | doaj-art-708567cf0edb4153b3df637ffb2b21cb |
| institution | OA Journals |
| issn | 2045-2322 |
| language | English |
| publishDate | 2024-04-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-708567cf0edb4153b3df637ffb2b21cb2025-08-20T02:10:56ZengNature PortfolioScientific Reports2045-23222024-04-011411810.1038/s41598-024-59337-4Circulating microRNA-155-3p levels predicts response to first line immunotherapy in patients with metastatic renal cell carcinomaMaryam Soleimani0Marisa Thi1Sajjad Janfaza2Gizem Ozcan3Sylwia Mazurek4Guliz Ozgun5Corinne Maurice-Dror6Bernhard Eigl7Kim Chi8Christian Kollmannsberger9Lucia Nappi10Division of Medical Oncology, British Columbia Cancer-Vancouver Cancer CentreAuckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, University of AucklandVancouver Prostate Centre, Department of Urologic Sciences, University of British ColumbiaVancouver Prostate Centre, Department of Urologic Sciences, University of British ColumbiaVancouver Prostate Centre, Department of Urologic Sciences, University of British ColumbiaDivision of Medical Oncology, British Columbia Cancer-Vancouver Cancer CentreDivision of Medical Oncology, British Columbia Cancer-Vancouver Cancer CentreDivision of Medical Oncology, British Columbia Cancer-Vancouver Cancer CentreDivision of Medical Oncology, British Columbia Cancer-Vancouver Cancer CentreDivision of Medical Oncology, British Columbia Cancer-Vancouver Cancer CentreDivision of Medical Oncology, British Columbia Cancer-Vancouver Cancer CentreAbstract Predictive biomarkers of response to immune checkpoint-based therapies (ICI) remain a critically unmet need in the management of advanced renal cell carcinoma (RCC). The complex interplay of the tumour microenvironment (TME) and the circulating immune response has proven to be challenging to decipher. MicroRNAs have gained increasing attention for their role in post-transcriptional gene expression regulation, particularly because they can have immunomodulatory properties. We evaluated the presence of immune-specific extracellular vesicle (EV) microRNAs in the plasma of patients with metastatic RCC (mRCC) prior to initiation of ICI. We found significantly lower levels of microRNA155-3p (miR155) in responders to ICI, when compared to non-responders. This microRNA has unique immunomodulatory properties, thus providing potential biological rationale for our findings. Our results support further work in exploring microRNAs as potential biomarkers of response to immunotherapy.https://doi.org/10.1038/s41598-024-59337-4 |
| spellingShingle | Maryam Soleimani Marisa Thi Sajjad Janfaza Gizem Ozcan Sylwia Mazurek Guliz Ozgun Corinne Maurice-Dror Bernhard Eigl Kim Chi Christian Kollmannsberger Lucia Nappi Circulating microRNA-155-3p levels predicts response to first line immunotherapy in patients with metastatic renal cell carcinoma Scientific Reports |
| title | Circulating microRNA-155-3p levels predicts response to first line immunotherapy in patients with metastatic renal cell carcinoma |
| title_full | Circulating microRNA-155-3p levels predicts response to first line immunotherapy in patients with metastatic renal cell carcinoma |
| title_fullStr | Circulating microRNA-155-3p levels predicts response to first line immunotherapy in patients with metastatic renal cell carcinoma |
| title_full_unstemmed | Circulating microRNA-155-3p levels predicts response to first line immunotherapy in patients with metastatic renal cell carcinoma |
| title_short | Circulating microRNA-155-3p levels predicts response to first line immunotherapy in patients with metastatic renal cell carcinoma |
| title_sort | circulating microrna 155 3p levels predicts response to first line immunotherapy in patients with metastatic renal cell carcinoma |
| url | https://doi.org/10.1038/s41598-024-59337-4 |
| work_keys_str_mv | AT maryamsoleimani circulatingmicrorna1553plevelspredictsresponsetofirstlineimmunotherapyinpatientswithmetastaticrenalcellcarcinoma AT marisathi circulatingmicrorna1553plevelspredictsresponsetofirstlineimmunotherapyinpatientswithmetastaticrenalcellcarcinoma AT sajjadjanfaza circulatingmicrorna1553plevelspredictsresponsetofirstlineimmunotherapyinpatientswithmetastaticrenalcellcarcinoma AT gizemozcan circulatingmicrorna1553plevelspredictsresponsetofirstlineimmunotherapyinpatientswithmetastaticrenalcellcarcinoma AT sylwiamazurek circulatingmicrorna1553plevelspredictsresponsetofirstlineimmunotherapyinpatientswithmetastaticrenalcellcarcinoma AT gulizozgun circulatingmicrorna1553plevelspredictsresponsetofirstlineimmunotherapyinpatientswithmetastaticrenalcellcarcinoma AT corinnemauricedror circulatingmicrorna1553plevelspredictsresponsetofirstlineimmunotherapyinpatientswithmetastaticrenalcellcarcinoma AT bernhardeigl circulatingmicrorna1553plevelspredictsresponsetofirstlineimmunotherapyinpatientswithmetastaticrenalcellcarcinoma AT kimchi circulatingmicrorna1553plevelspredictsresponsetofirstlineimmunotherapyinpatientswithmetastaticrenalcellcarcinoma AT christiankollmannsberger circulatingmicrorna1553plevelspredictsresponsetofirstlineimmunotherapyinpatientswithmetastaticrenalcellcarcinoma AT lucianappi circulatingmicrorna1553plevelspredictsresponsetofirstlineimmunotherapyinpatientswithmetastaticrenalcellcarcinoma |